Bishop Jonathan, Furman Mark, Thomson Mike
Sheffield Children's Hospital, Sheffield, UK.
J Pediatr Gastroenterol Nutr. 2007 Jul;45(1):50-5. doi: 10.1097/MPG.0b013e318049cbcc.
Gastroesophageal reflux occurs in the majority of infants, with severity ranging from asymptomatic to severe esophagitis and failure to thrive. Omeprazole is recognized as a safe and effective treatment of gastroesophageal reflux in older children, at an initial dosage of 0.7 mg x kg(-1) x day(-1). To our knowledge, no dose-finding studies have been carried out in children under 2 years of age. The aim of the present study was to prospectively determine the dosage of omeprazole required to treat symptomatic gastroesophageal reflux in children younger than 2 years.
Children under 2 years with clinical suspicion of gastroesophageal reflux underwent 24-hour dual-channel intraesophageal/gastric pH monitoring. A reflux index above 10% in children under 1 year and above 6% in children older than 1 year was deemed significant. Treatment with omeprazole at an initial dosage of 0.7 mg x kg(-1) x day(-1) (in 2 divided doses) was followed by dual-channel pH study after 14 days. The dosage was increased in increments of 0.7 mg x kg(-1) x day(-1), and pH studies were repeated until the gastroesophageal reflux was controlled.
Ten children (5 male, 5 female), mean age 7.75 months (range, 1.25-20 months), were investigated. The initial median reflux index was 18.5% (range, 6.5%-56.3%). Follow-up median reflux index was improved at 1.6% (0.1%-8.1%) (P < 0.05). The median dosage required was 1.05 mg x kg(-1) x day(-1). Four children required 1.4 mg x kg(-1) x day(-1), and 1 required 2.8 mg x kg(-1) x day(-1). Corrected reflux index improved from 34.8% (16.8%-90.8%) to 20.1% (0.4%-100%) but did not achieve statistical significance. There were no serious complications or side effects.
Omeprazole is an effective treatment for gastroesophageal reflux in children younger than 2 years. The majority respond to a dosage of 0.7 mg x kg(-1) x day(-1), but increased dosages up to 2.8 mg x kg(-1) x day(-1) may be required.
大多数婴儿都会发生胃食管反流,严重程度从无症状到严重食管炎及生长发育迟缓不等。奥美拉唑被认为是治疗大龄儿童胃食管反流的一种安全有效的药物,初始剂量为0.7mg·kg⁻¹·d⁻¹。据我们所知,尚未对2岁以下儿童进行过剂量探索研究。本研究的目的是前瞻性地确定治疗2岁以下有症状胃食管反流儿童所需的奥美拉唑剂量。
对临床怀疑有胃食管反流的2岁以下儿童进行24小时双通道食管/胃pH监测。1岁以下儿童反流指数高于10%,1岁以上儿童高于6%被视为有意义。初始剂量为0.7mg·kg⁻¹·d⁻¹(分2次给药)的奥美拉唑治疗14天后进行双通道pH研究。剂量以0.7mg·kg⁻¹·d⁻¹的增量增加,并重复进行pH研究,直到胃食管反流得到控制。
对10名儿童(5名男性,5名女性)进行了研究,平均年龄7.75个月(范围1.25 - 20个月)。初始反流指数中位数为18.5%(范围6.5% - 56.3%)。随访时反流指数中位数改善至1.6%(0.1% - 8.1%)(P < 0.05)。所需中位数剂量为1.05mg·kg⁻¹·d⁻¹。4名儿童需要1.4mg·kg⁻¹·d⁻¹,1名儿童需要2.8mg·kg⁻¹·d⁻¹。校正后的反流指数从34.8%(16.8% - 90.8%)改善至20.1%(0.4% - 100%),但未达到统计学显著性。未出现严重并发症或副作用。
奥美拉唑是治疗2岁以下儿童胃食管反流的有效药物。大多数儿童对0.7mg·kg⁻¹·d⁻¹的剂量有反应,但可能需要增加剂量至2.8mg·kg⁻¹·d⁻¹。